Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.20USD
16 Feb 2018
Change (% chg)

$0.09 (+2.19%)
Prev Close
$4.11
Open
$4.13
Day's High
$4.34
Day's Low
$4.12
Volume
265,460
Avg. Vol
291,103
52-wk High
$9.85
52-wk Low
$3.77

Latest Key Developments (Source: Significant Developments)

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 08:00am EST 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 06:23am EDT 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article

Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection
Monday, 18 Sep 2017 08:00am EDT 

Sept 18 (Reuters) - Inovio Pharmaceuticals Inc :Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection.Inovio Pharmaceuticals Inc - Korean Ministry Of Food and Drug safety approved initiation of a study to evaluate GLS-5300.  Full Article

Inovio Pharmaceuticals reports Q2 loss per share $0.13
Tuesday, 8 Aug 2017 04:14pm EDT 

Aug 9 (Reuters) - Inovio Pharmaceuticals Inc -:Inovio Pharmaceuticals reports 2017 second quarter financial results.Q2 loss per share $0.13.Q2 revenue $20.4 million versus $6.2 million.Q2 revenue view $16.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share
Wednesday, 19 Jul 2017 10:09pm EDT 

July 19 (Reuters) - Inovio Pharmaceuticals Inc ::Inovio announces pricing of public offering of common stock.Says public offering of 12.5 million common shares priced at $6.00 per share.  Full Article

Inovio announces proposed public offering of common stock
Tuesday, 18 Jul 2017 04:01pm EDT 

July 18 (Reuters) - Inovio Pharmaceuticals Inc :Inovio announces proposed public offering of common stock.Inovio Pharmaceuticals Inc - intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.Inovio Pharmaceuticals - anticipates using net proceeds for general corporate purposes, including clinical trial expenses, research and development expenses.  Full Article

Inovio begins phase 3 clinical trial of VGX-3100
Thursday, 8 Jun 2017 06:00am EDT 

June 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio begins phase 3 clinical trial of VGX-3100 for the treatment of HPV-related cervical pre-cancer.Plans to immediately begin recruiting patients for phase 3 trial.Pivotal data from program will support potential licensure of VGX-3100 as first immunotherapy for this disease​.  Full Article

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS